Business
SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout
SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June
About this update from Synact Pharma Ab
SynAct Pharma announced this morning that the last patient has completed dosing in the phase IIb ADVANCE study, the company's pivotal trial of resomelagon (AP1189) in newly diagnosed rheumatoid arthritis. With dosing now closed across more than 30 sites, attention shifts to the topline readout, which the company continues to expect in June 2026 . Read the full article at biostock.se: SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout This is a press release from BioStock - Connecting Innovation & Capital . https://www.biostock.se/ Follow BioStock Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter Follow BioStock on social media: LinkedIn and Facebook! About BioStock BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments. BioStock – Connecting Innovation & Capital. © Modular Finance, source Nordic Press Releases